Navigation Links
IntelligentMDx Receives FDA Clearance for IMDx VanR for Abbott m2000 assay
Date:7/29/2013

CAMBRIDGE, Mass., July 29, 2013 /PRNewswire/ -- IntelligentMDx (privately held) announced today that the U.S. Food and Drug Administration (FDA) has cleared its automated molecular diagnostic test that detects the presence of vanA and vanB genes that can be associated with vancomycin-resistant enterococci (VRE). This is one of the tests in IMDx's portfolio of infectious disease products to be cleared by the FDA for use on Abbott's fully automated m2000 platform.

VRE are bacteria which have become resistant to the antibiotic vancomycin, and are responsible for a variety of healthcare-associated infections, including surgical wound, urinary tract, and bloodstream infections. The IMDx VanR for Abbott m2000 assay is intended to be used as an aid to identify, prevent and control vancomycin-resistant colonization in healthcare settings.

The automated nature of the IMDx VanR for Abbott m2000 test allows laboratories to obtain results for up to 46 patient samples in less than 3 hours, and up to 94 patient samples in less than 4 hours. The assay is performed directly on human peri-rectal swabs, rectal swabs, or stool specimens from patients at risk for VRE colonization.

"We are proud to have received FDA clearance so that IMDx can offer a diagnostic solution to aid in the identification of vancomycin-resistant colonization in hospital settings in the U.S.," says Dr. Alice Jacobs Nesselrodt, Chairman and CEO of IMDx. "FDA clearance of the IMDx VanR for Abbott m2000 assay is a step toward the fulfillment of IMDx's mission to make clinically impactful molecular diagnostic testing solutions available as broadly as possible. We look forward to continuing to expand our menu of diagnostic tests in the U.S."

The IMDx VanR for Abbott m2000 assay is part of a broad real-time PCR test menu designed, developed, and manufactured for use on Abbott's RealTime m2000 system under a multi-year distribution agreement with Abbott.

About IMDx

Based in Cambridge, MA, IMDx (www.IntelligentMDx.com) is an innovator of unique proprietary molecular tests equipped with features and benefits to port onto nearly any molecular testing system. IMDx's competitive advantage lies in its extensive bioinformatics capabilities, enabling the production of rapid, low cost high quality products with top performance characteristics to empower clinicians to provide care with greater certainty. Current and future product lines include tests for Infectious Diseases (Healthcare Associated Infections, respiratory diseases, STDs, prenatal testing), oncology and other human genetic targets. The IMDx facilities are ISO 13485:2003 certified and all of the IMDx products are developed and manufactured within a regulatory compliant (FDA QSR, CE-IVDD and cGMP) environment.

CONTACT: Renda Hawwa, +1-617-871-6417, cc@intelligentmdx.com


'/>"/>
SOURCE IMDx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IntelligentMDx Announces CE-Marking of a new high-throughput test for Group B Streptococcus intended to improve womens health and prenatal care
2. IntelligentMDx gibt CE-Kennzeichnung eines Tests zum Nachweis und zur Differenzierung von Influenza A, Influenza B und respiratorischem Synzytialvirus in Echtzeit-System Abbott m2000 bekannt
3. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
4. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
5. Nephros Receives 510(k) Clearance for Hemodiafiltration System
6. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
7. BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award
8. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
9. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
10. Alexza Receives Complete Response Letter for Adasuve™ NDA
11. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... New York , March 28, 2017 ... a largely consolidated vendor landscape, with the top three ... Agilent Technologies accounting for a significant 49% of the ... a recent report. The vendor landscape is intensely competitive ... share in the overall market. These factors have restricted ...
(Date:3/28/2017)... and TEL AVIV, Israel , March 28, ... in Israel . This new business entity, Emosis ... mostly dedicated to research and development of novel assays complementing the ... also, when relevant, locally support commercialization and sales development of Emosis ... This strategic ...
(Date:3/28/2017)... 2017  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a ... and other unmet medical needs, announced today two ... Research annual meeting.  The first poster to be ... of ENMD-2076 in Combination with Anti-PD1 in Syngeneic ... be presented on April 4 is entitled " ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce that ... Mr. Still was selected through a careful months-long search by the RBMA Board of ... our members, has been a part of building the RBMA since 1992,” said RBMA ...
(Date:3/28/2017)... ... ... With less than 10,000 dermatologists in the United States and more than ... the desire to conquer breakouts and eliminate skincare stress is widespread. Curology , ... released its inaugural survey on the State of Acne in America. , The ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally invasive ... “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists about ... aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency ... in early March. , The seed processing plant opened in Marshallville in 2006, and ... The new office allows opportunity for transition of Patten Seed operations to the Middle ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that ... Donald Quinn. , “There were things that his parents and teachers had asked of him ... way that he was going to defy the Almighty Creator. There were some who would ...
Breaking Medicine News(10 mins):